Research Progress on circulating biomarkers for immunotherapy in Non-Small Cell Lung Cancer
10.3760/cma.j.cn114452-20221108-00662
- VernacularTitle:非小细胞肺癌免疫治疗相关循环生物标志物研究进展
- Author:
Yangyang ZHAO
1
;
Zhansheng JIANG
;
Zhanyu PAN
Author Information
1. 天津医科大学肿瘤医院 中西医结合科，国家恶性肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心，天津市肿瘤免疫与生物治疗重点实验室，天津300060
- Keywords:
Biomarkers;
Non-small-cell lung cancer;
Immunotherapy
- From:
Chinese Journal of Laboratory Medicine
2023;46(12):1324-1330
- CountryChina
- Language:Chinese
-
Abstract:
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, and immunotherapy has become a relatively common treatment for NSCLC. The use of biomarkers to screen out people with high benefit from immunotherapy could help to timely grasp the therapeutic information of NSCLC patients and meet the current challenges faced by immunotherapy. Compared with traditional markers such as programmed death-ligand protein 1(PD-L1) expression fraction, circulating biomarkers have the characteristics of non-invasion, convenient collection of materials, and dynamically evaluating the prognosis of patients and observing the efficacy of immunotherapy in the process of immunotherapy, which has a broad application prospect.
